The inspection was carried out at the company’s Unit 9 facility at Zydus Biotech Park in Changodar, Ahmedabad, from 16 February to 19 February, 2026, the drug maker said in a regulatory filing.

The company added that the inspection concluded without any observations, indicating compliance with the regulator’s standards.

Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

The company’s consolidated net profit rose 7.7% to Rs 1,102.64 crore on 32.3% increase in revenue from operations to Rs 6,780.40 crore in Q3 FY26 over Q3 FY25.

Shares of Zydus Lifesciences rose 0.08% to Rs 903 on the BSE.